PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
SciClone Pharmaceuticals (6600.HK)
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN

KYG4271B1023

Sector

Healthcare

Highlights

Market Cap

HK$11.80B

PE Ratio

10.12

Year Range

HK$16.04 - HK$18.72

Target Price

HK$16.71

Share Price Chart


Loading data...

Compare to other instruments

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Performance

Performance Chart

The chart shows the growth of an initial investment of HK$10,000 in SciClone Pharmaceuticals, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Returns By Period


6600.HK

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

^GSPC (Benchmark)

YTD

-3.72%

1M

-7.61%

6M

-0.89%

1Y

8.39%

5Y*

19.76%

10Y*

10.43%

*Annualized

Monthly Returns

The table below presents the monthly returns of 6600.HK, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024-20.26%17.30%23.20%11.85%3.12%1.19%34.48%
202314.35%4.11%3.75%15.82%-11.47%4.35%2.66%-12.57%5.60%3.10%32.04%2.35%74.55%
2022-2.89%-6.55%3.57%1.97%-0.23%9.71%-10.80%-7.99%-13.31%-7.27%9.93%31.38%-0.05%
2021-17.23%1.41%-6.72%1.22%-23.36%-14.97%7.11%1.73%-14.27%-4.63%-53.99%

Risk-Adjusted Performance

Risk-Adjusted Performance Rank

With an overall rank of 92, 6600.HK is among the top 8% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.


The Risk-Adjusted Performance Rank of 6600.HK is 9292
Overall Rank
The Sharpe Ratio Rank of 6600.HK is 9595
Sharpe Ratio Rank
The Sortino Ratio Rank of 6600.HK is 9292
Sortino Ratio Rank
The Omega Ratio Rank of 6600.HK is 9292
Omega Ratio Rank
The Calmar Ratio Rank of 6600.HK is 9191
Calmar Ratio Rank
The Martin Ratio Rank of 6600.HK is 9191
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

Risk-Adjusted Performance Indicators

The charts below present risk-adjusted performance metrics for SciClone Pharmaceuticals (6600.HK) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.


Sharpe ratio
No data
6600.HK
^GSPC

There is not enough data available to calculate the Sharpe ratio for SciClone Pharmaceuticals. We calculate this metric based on the past 12 months of trading data. Please check back later for updated information.


Rolling 12-month Sharpe Ratio
6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Dividends

Dividend History

SciClone Pharmaceuticals provided a 0.00% dividend yield over the last twelve months, with an annual payout of HK$0.00 per share.


3.00%3.50%4.00%HK$0.00HK$0.10HK$0.20HK$0.30HK$0.4020222023
Dividends
Dividend Yield
PeriodTTM20232022
DividendHK$0.00HK$0.39HK$0.35

Dividend yield

0.00%2.80%4.22%

Monthly Dividends

The table displays the monthly dividend distributions for SciClone Pharmaceuticals. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2024HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00
2023HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.39HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.39
2022HK$0.35HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.00HK$0.35

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Worst Drawdowns

The table below displays the maximum drawdowns of the SciClone Pharmaceuticals. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SciClone Pharmaceuticals was 68.49%, occurring on Oct 28, 2022. Recovery took 349 trading sessions.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-68.49%Mar 4, 2021409Oct 28, 2022349Apr 2, 2024758
-0.65%May 28, 20242May 29, 20242May 31, 20244
-0.64%Jun 11, 20242Jun 12, 20246Jun 20, 20248
-0.55%Apr 16, 202411Apr 30, 20242May 3, 202413
-0.45%Apr 8, 20242Apr 9, 20243Apr 12, 20245

Volatility

Volatility Chart

The current SciClone Pharmaceuticals volatility is 1.18%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.


6600.HK (SciClone Pharmaceuticals)
Benchmark (^GSPC)

Financials

Financial Performance

The chart below illustrates the trends in the financial health of SciClone Pharmaceuticals over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

Annual
Quarterly

0.0

Historical P/E Ratio Chart

The chart below displays the historical trend of the price-to-earnings (P/E) ratio for SciClone Pharmaceuticals.


Loading data...

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
PortfoliosLab logo
Performance Analysis
Portfolio AnalysisPortfolio PerformanceStock ComparisonSharpe RatioMartin RatioTreynor RatioSortino RatioOmega RatioCalmar RatioSummers Ratio
Community
Discussions


Disclaimer

The information contained herein does not constitute investment advice and made available for educational purposes only. Prices and returns on equities are listed without consideration of fees, commissions, taxes, penalties, or interest payable due to purchasing, holding, or selling.

Copyright © 2025 PortfoliosLab